PROCESSORS

TORONTO, CANADA -- Platform Computing Inc., a leader in distributed computing software, announced today that Entelos, Inc. will integrate Platform's distributed computing software, Platform LSF(R) and Platform LSF ActiveCluster(TM), with its PhysioLab(TM) disease simulation platform. This end-to-end solution will allow Entelos to harness underutilized compute power across the enterprise, enabling its scientists to run faster simulations and accelerate the in silico (in computer) discovery and development of new drug therapies. Platform will provide workload management with Platform LSF across Entelos' server farms and will enable distributed desktop processing with Platform LSF ActiveCluster, which harnesses unused desktop cycles to process compute-intensive tasks efficiently, complete workloads faster, and increase user productivity. "We chose Platform's solution because we wanted a commercially supported, end-to-end package from a partner that has extensive experience in providing solutions to the life sciences community," said Alex Bangs, CTO, Entelos. "Platform LSF ActiveCluster was a deciding factor -- with ActiveCluster we can go beyond traditional distributed computing and expand our processing power by utilizing idle desktops. As we plan to offer this technology to our pharmaceutical partners, this will provide as significant a benefit to them as it will to us." The leader in predictive biosimulation for in silico drug discovery and development, Entelos partners with pharmaceutical and biotech organizations worldwide to develop effective new treatments for disease. With its patented PhysioLab technology, Entelos develops dynamic large-scale computer models of human disease and uses them to rapidly simulate experiments on virtual patients that could take months or years to do in the lab or clinic. Each PhysioLab provides a framework for integrating data (including genomic, proteomic, physiologic, and environmental) in the context of a disease, with a focus on understanding and determining clinical responses to potential treatment. "Entelos has a very exciting technology that can accelerate the discovery and development of new drugs and therapeutic interventions," said Yury Rozenman, director, Life Sciences, Platform. "With Platform LSF and LSF ActiveCluster, Entelos has the scalability and additional compute power to do more analyses and computations, accelerating disease research for pharmaceutical companies. With Platform's solution, Entelos can represent more virtual patients and analyze them faster than ever before, speeding up the process for its research and its partners." Entelos' in silico R&D increases productivity at every stage of drug discovery and development (lead generation, lead optimization, and clinical development). Entelos is applying in silico R&D today to help its pharmaceutical partners identify and characterize novel pathways and genes; prioritize and evaluate targets and candidates; plan and optimize clinical trials and experiments; assess the clinical impact of therapeutic approaches on different patient populations; and relate genomic, proteomic, and in vitro data to clinical outcomes. For more information visit www.platform.com or www.entelos.com